AbbVie Inc. Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent
AbbVie Inc. (ABBV) reported Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent of -$8.00 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-08.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTranslationAdjustmentTaxPortionAttributableToParent · last filed 2020-05-08
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2020-03-31 was -$8.00M, a 900.00% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2019-12-31 was $6.00M.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2019-09-30 was -$16.00M, a 633.33% decline year-over-year.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for the quarter ending 2019-06-30 was $5.00M.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2019 was -$4.00M.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2018 was -$18.00M, a 152.94% decline from fiscal 2017.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2017 was $34.00M.
- AbbVie Inc. other comprehensive income (loss), foreign currency translation adjustment, tax, portion attributable to parent for fiscal 2016 was -$31.00M.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2020-03-31 | -$8.00M 10-Q · filed 2020-05-08 | -$2.00M derived: sum of 2 quarters · filed 2020-05-08 | -$18.00M derived: sum of 3 quarters · filed 2020-05-08 | -$13.00M derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-12-31 | $6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | -$10.00M derived: sum of 2 quarters · filed 2020-02-21 | -$5.00M derived: sum of 3 quarters · filed 2020-02-21 | -$4.00M 10-K · filed 2020-02-21 |
| 2019-09-30 | -$16.00M 10-Q · filed 2019-11-06 | -$11.00M derived: sum of 2 quarters · filed 2019-11-06 | -$10.00M 10-Q · filed 2019-11-06 | -$12.00M derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-06-30 | $5.00M 10-Q · filed 2019-08-05 | $6.00M 10-Q · filed 2019-08-05 | $4.00M derived: sum of 3 quarters · filed 2020-05-08 | $7.00M derived: sum of 4 quarters · filed 2020-05-08 |
| 2019-03-31 | $1.00M 10-Q · filed 2020-05-08 | -$1.00M derived: sum of 2 quarters · filed 2020-05-08 | $2.00M derived: sum of 3 quarters · filed 2020-05-08 | -$14.00M derived: sum of 4 quarters · filed 2020-05-08 |
| 2018-12-31 | -$2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.00M derived: sum of 2 quarters · filed 2020-02-21 | -$15.00M derived: sum of 3 quarters · filed 2020-02-21 | -$18.00M 10-K · filed 2020-02-21 |
| 2018-09-30 | $3.00M 10-Q · filed 2019-11-06 | -$13.00M derived: sum of 2 quarters · filed 2019-11-06 | -$16.00M 10-Q · filed 2019-11-06 | -$22.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | -$16.00M 10-Q · filed 2019-08-05 | -$19.00M 10-Q · filed 2019-08-05 | -$25.00M derived: sum of 3 quarters · filed 2020-02-21 | -$18.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | -$3.00M 10-Q · filed 2019-05-03 | -$9.00M derived: sum of 2 quarters · filed 2020-02-21 | -$2.00M derived: sum of 3 quarters · filed 2020-02-21 | $31.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | -$6.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $1.00M derived: sum of 2 quarters · filed 2020-02-21 | $34.00M derived: sum of 3 quarters · filed 2020-02-21 | $34.00M 10-K · filed 2020-02-21 |
| 2017-09-30 | $7.00M 10-Q · filed 2018-11-07 | $40.00M derived: sum of 2 quarters · filed 2018-11-07 | $40.00M 10-Q · filed 2018-11-07 | -$21.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $33.00M 10-Q · filed 2018-08-07 | $33.00M 10-Q · filed 2018-08-07 | -$28.00M derived: sum of 3 quarters · filed 2019-02-27 | -$18.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $0.00 10-Q · filed 2018-05-04 | -$61.00M derived: sum of 2 quarters · filed 2019-02-27 | -$51.00M derived: sum of 3 quarters · filed 2019-02-27 | -$72.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | -$61.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$51.00M derived: sum of 2 quarters · filed 2019-02-27 | -$72.00M derived: sum of 3 quarters · filed 2019-02-27 | -$31.00M 10-K · filed 2019-02-27 |
| 2016-09-30 | $10.00M 10-Q · filed 2017-11-07 | -$11.00M derived: sum of 2 quarters · filed 2017-11-07 | $30.00M 10-Q · filed 2017-11-07 | -$11.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | -$21.00M 10-Q · filed 2017-08-07 | $20.00M 10-Q · filed 2017-08-07 | -$21.00M derived: sum of 3 quarters · filed 2018-02-16 | -$11.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | $41.00M 10-Q · filed 2017-05-05 | $0.00 derived: sum of 2 quarters · filed 2018-02-16 | $10.00M derived: sum of 3 quarters · filed 2018-02-16 | $31.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | -$41.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | -$31.00M derived: sum of 2 quarters · filed 2018-02-16 | -$10.00M derived: sum of 3 quarters · filed 2018-02-16 | -$139.00M 10-K · filed 2018-02-16 |
| 2015-09-30 | $10.00M 10-Q · filed 2016-11-07 | $31.00M derived: sum of 2 quarters · filed 2016-11-07 | -$98.00M 10-Q · filed 2016-11-07 | -$166.00M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | $21.00M 10-Q · filed 2016-08-05 | -$108.00M 10-Q · filed 2016-08-05 | -$176.00M derived: sum of 3 quarters · filed 2017-02-17 | -$252.00M derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$129.00M 10-Q · filed 2016-05-06 | -$197.00M derived: sum of 2 quarters · filed 2017-02-17 | -$273.00M derived: sum of 3 quarters · filed 2017-02-17 | -$283.00M derived: sum of 4 quarters · filed 2017-02-17 |
| 2014-12-31 | -$68.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$144.00M derived: sum of 2 quarters · filed 2017-02-17 | -$154.00M derived: sum of 3 quarters · filed 2017-02-17 | -$158.00M 10-K · filed 2017-02-17 |
| 2014-09-30 | -$76.00M 10-Q · filed 2015-11-06 | -$86.00M derived: sum of 2 quarters · filed 2015-11-06 | -$90.00M 10-Q · filed 2015-11-06 | -$16.00M derived: sum of 4 quarters · filed 2016-02-19 |
| 2014-06-30 | -$10.00M 10-Q · filed 2015-08-07 | -$13.00M 10-Q · filed 2015-08-07 | $60.00M derived: sum of 3 quarters · filed 2016-02-19 | |
| 2014-03-31 | -$3.00M 10-Q · filed 2015-05-08 | $70.00M derived: sum of 2 quarters · filed 2016-02-19 | ||
| 2013-12-31 | $73.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | $71.00M 10-K · filed 2016-02-19 | ||
| 2013-09-30 | -$2.00M 10-Q · filed 2014-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |